Literature DB >> 26876798

Sarcopenia and survival in patients undergoing pancreatic resection.

Jill K Onesti1, G Paul Wright2, Sarah E Kenning2, Mark T Tierney3, Alan T Davis4, Michael G Doherty5, Mathew H Chung6.   

Abstract

BACKGROUND: Recent studies have suggested that lean core muscle area may predict outcomes from major abdominal surgeries. Pancreatic resections have been independently analyzed less frequently.
METHODS: Pancreatic resections from 2005 to 2012 were reviewed. Sarcopenia was defined as the lowest tertile for lean psoas muscle area (LPMA). Preoperative risk factors, including comorbidities, albumin, weight loss, age and gender, were analyzed with a primary endpoint of overall survival. Secondary endpoints included complications, discharge destination and readmission.
RESULTS: The study sample of 270 patients had complications in 42% of patients, with 26% developing serious complication. The majority (80%) were discharged home, and 1.9% died in the peri-operative period. The mean length of follow up was 31.2 months (range 0-94), and 37% required at least one readmission. LPMA was predictive of discharge destination for females (p = 0.038). Sarcopenia was predictive of readmission in males, compared to subjects in the second LPMA tertile (HR 0.3; 95% CI: 0.1-0.9). In all male subjects, including a subset with adenocarcinoma, patients with sarcopenia were more likely to die than males in the highest LPMA tertile (HR: 2.6; 95% CI: 1.4-4.8 and HR: 2.4; 95% CI: 1.2-4.9, respectively). In all patients with pancreatic ductal adenocarcinoma, transfusion (HR: 1.9; 95% CI: 1.1-3.4) and positive margins (HR: 2.0; 95% CI: 1.2-3.3) were the only factors predictive of overall survival.
CONCLUSIONS: Sarcopenia appears to be a predictor of overall survival in male patients undergoing pancreatic resections, but not specifically for patients with pancreatic ductal adenocarcinoma. As prospective data in future studies are identified, sarcopenia may become a useful tool in predicting outcomes.
Copyright © 2016 IAP and EPC. Published by Elsevier India Pvt Ltd. All rights reserved.

Entities:  

Keywords:  Mortality; Outcomes; Pancreatectomy; Predictors; Sarcopenia; Survival

Mesh:

Year:  2016        PMID: 26876798     DOI: 10.1016/j.pan.2016.01.009

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  18 in total

1.  Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy.

Authors:  Noriko Ishii; Yoshinori Iwata; Hiroki Nishikawa; Hirayuki Enomoto; Nobuhiro Aizawa; Akio Ishii; Yuho Miyamoto; Yukihisa Yuri; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Ryo Takata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

2.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

3.  A low psoas muscle volume predicts longer hospitalization and cancer recurrence in upper urinary tract urothelial carcinoma.

Authors:  Sohgo Tsutsumi; Takashi Kawahara; Jun-Ichi Teranishi; Masahiro Yao; Hiroji Uemura
Journal:  Mol Clin Oncol       Date:  2017-12-12

4.  Association Between Sarcopenia and Mortality in Patients Undergoing Surgical Excision of Head and Neck Cancer.

Authors:  Lucas Stone; Brennan Olson; Alia Mowery; Stephanie Krasnow; Angie Jiang; Ryan Li; Joshua Schindler; Mark K Wax; Peter Andersen; Daniel Marks; Virginie Achim; Daniel Clayburgh
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2019-07-01       Impact factor: 6.223

5.  Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi
Journal:  J Gastrointest Surg       Date:  2018-02-01       Impact factor: 3.452

6.  Psoas muscle size as a magnetic resonance imaging biomarker of progression of pancreatitis.

Authors:  Andre E Modesto; Charlotte E Stuart; Jaelim Cho; Juyeon Ko; Ruma G Singh; Maxim S Petrov
Journal:  Eur Radiol       Date:  2020-02-10       Impact factor: 5.315

Review 7.  Implications of low muscle mass across the continuum of care: a narrative review.

Authors:  Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield
Journal:  Ann Med       Date:  2018-09-12       Impact factor: 4.709

8.  Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.

Authors:  Tetsuya Yumioka; Masashi Honda; Ryoma Nishikawa; Shogo Teraoka; Yusuke Kimura; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2019-09-13       Impact factor: 3.402

9.  Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy.

Authors:  William H Jin; Eric A Mellon; Jessica M Frakes; Gilbert Z Murimwa; Pamela J Hodul; Jose M Pimiento; Mokenge P Malafa; Sarah E Hoffe
Journal:  J Gastrointest Oncol       Date:  2018-02

10.  Low Lean Mass With and Without Obesity, and Mortality: Results From the 1999-2004 National Health and Nutrition Examination Survey.

Authors:  John A Batsis; Todd A Mackenzie; Rebecca T Emeny; Francisco Lopez-Jimenez; Stephen J Bartels
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-10-01       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.